Dasiglucagon
ZP-4207, ZP-GA-1
Approved
Zealand Pharma A/S
Diabetes Mellitus, Type 1, Congenital Hyperinsulinism, Hypoglycemia, Hyperinsulinism
NCT03216226
NCT03777176
NCT03895697
NCT03667053
NCT03941236
NCT03688711
NCT03378635
NCT03840278
NCT04172441
NCT02971228
NCT04764968
NCT02916251
NCT04449692
NCT03984370
NCT02660008
NCT03735225
NCT02367053
NCT02390141
NCT04192019
Drug
Other, Drug
Drug
Drug
Drug
Drug
Drug
Drug, Device
Drug
Drug, Device
Drug
Drug
Other, Drug
Other, Drug
Drug
Drug
Drug
Drug
Drug
Hypoglycemia; Diabetes Mellitus, Type 1
Congenital Hyperinsulinism
Hypoglycemia; Diabetes Mellitus, Type 1
Hypoglycemia
Congenital Hyperinsulinism
Hypoglycemia; Diabetes Mellitus, Type 1
Hypoglycemia; Diabetes Mellitus, Type 1
Type 1 Diabetes Mellitus
Congenital Hyperinsulinism
Diabetes Mellitus, Type 1
Type 1 Diabetes; Hypoglycemia
Diabetes Mellitus Type 1
Type 1 Diabetes; Hypoglycemia
Hyperinsulinemic Hypoglycemia; Postprandial Hypoglycemia
Hypoglycemia
Hypoglycemia
Hypoglycemia
Hypoglycemia
Type 1 Diabetes; Hypoglycemia
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Early Phase 1
Completed
Completed
Completed
Completed
Enrolling by invitation
Completed
Completed
Completed
Recruiting
Completed
Not yet recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Not yet recruiting
Glucagon (rDNA origin, Lilly)
Approved
Eli Lilly And Company
Diabetes Mellitus, Type 1, Hypoglycemia
NCT03533179
NCT02402933
NCT02656069
NCT04461015
NCT03738865
NCT01994746
NCT01997411
NCT03650582
NCT03490942
NCT02626936
NCT01300260
NCT02778113
NCT03526445
NCT04300049
NCT02701257
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Other, Drug, Device
Biological, Drug
Drug
Drug
Other, Drug
Drug, Device
Drug Overdose; Overdose of Beta-adrenergic Blocking Drug
Hypoglycemia; Diabetes Mellitus
Hypoglycemia; Diabetes Mellitus, Type 1
Healthy
Insulin Hypoglycemia; Type 1 Diabetes Mellitus; Severe Hypoglycemia
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 1
Obesity
Hypoglycemia Unawareness; Diabetes Mellitus, Type 1
Type 1 Diabetes
Diabetes Mellitus, Type 2
Healthy
Non-Alcoholic Fatty Liver Disease; Total Pancreatectomy; Diabetes Mellitus
Insulin Sensitivity
Diabetes Mellitus Type 1
Phase 4
Phase 3
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2/Phase 3
Phase 2
Phase 2
Phase 1
Phase 1
N/A
N/A
N/A
Completed
Completed
Completed
Recruiting
Completed
Completed
Completed
Unknown status
Terminated
Completed
Completed
Completed
Completed
Recruiting
Terminated
Glucagon (rDNA origin, Novo Nordisk)
GL-G
Approved
Novo Nordisk A/S
Hypoglycemia
NCT03533179
NCT04053712
NCT02232971
NCT03216226
NCT00929812
NCT03378635
NCT02379299
NCT01871870
NCT02910518
NCT02240043
NCT01483651
NCT04007809
NCT03526445
Drug
Drug, Device
Other, Drug
Drug
Drug
Drug
Device
Device
Drug
Other
Drug
Other
Drug
Drug Overdose; Overdose of Beta-adrenergic Blocking Drug
Type 1 Diabetes; Hypoglycemia
Diabetes Mellitus, Type 1
Hypoglycemia; Diabetes Mellitus, Type 1
Healthy Subjects; Obesity; Diabetes Mellitus, Type 1
Hypoglycemia; Diabetes Mellitus, Type 1
Type 1 Diabetes
Type 1 Diabetes Mellitus
Type1 Diabetes Mellitus
Aging
Type 1 Diabetes Mellitus
Type1diabetes
Non-Alcoholic Fatty Liver Disease; Total Pancreatectomy; Diabetes Mellitus
Phase 4
Phase 4
Phase 4
Phase 3
Phase 3
Phase 3
Phase 2/Phase 3
Phase 2
Phase 1
N/A
N/A
N/A
N/A
Completed
Recruiting
Unknown status
Completed
Unknown status
Completed
Withdrawn
Completed
Completed
Completed
Completed
Recruiting
Completed
Glucagon
MP-123456B
Approved
Eli Lilly And Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemia, Diabetes Mellitus
Type 1 Diabetes Mellitus With Hypoglycemia
Type1diabetes
Glucagon (Xeris Pharmaceuticals)
Approved
Xeris Pharmaceuticals
Hypoglycemia, Hyperinsulinism
NCT03770637
NCT02733588
NCT03841526
Other, Drug
Drug
Other, Drug
Hyperinsulinemic Hypoglycemia
Hypoglycemia; Complications of Bariatric Procedures
Hypoglycemia
Completed
Completed
Completed
Glucagon intranasal (Eli Lilly/Locemia Solutions)
AMG504-1, LY-900018
Approved
Amg Medical, Locemia Solutions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemia, Diabetes Mellitus
NCT01959334
NCT03421379
NCT02402933
NCT02171130
NCT01556594
NCT02778113
NCT02806960
NCT02740829
NCT03339453
NCT02778100
NCT02806973
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug-specific Antibodies; Diabetes Mellitus
Diabetes Mellitus
Hypoglycemia; Diabetes Mellitus
Hypoglycemia; Diabetes Mellitus; Drug-Specific Antibodies
Hypoglycemia
Healthy
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Diabetes
Hypoglycemia; Diabetes Mellitus, Type 1
Common Cold
Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
Phase 3
Phase 3
Phase 3
Phase 3
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Completed
Completed
Completed
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
PRT-001
PRT-001
Phase 3 Clinical
Particle Therapeutics
Hypoglycemia
BI-456906
BI-456906
Phase 2 Clinical
Zealand Pharma A/S
Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Obesity
NCT04771273
NCT04667377
NCT04153929
NCT03175211
NCT03591718
NCT04384081
Non-alcoholic Steatohepatitis (NASH)
Obesity
Diabetes Mellitus, Type 2
Healthy
Obesity
Healthy
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Not yet recruiting
Not yet recruiting
Recruiting
Completed
Completed
Completed
LGD-6972
LGD-6972, MB-11262, RVT-1502
Phase 2 Clinical
Ligand Pharmaceuticals Inc
Diabetes Mellitus, Type 2
NCT02851849
NCT02250222
NCT02672839
NCT01919684
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes Mellitus
Phase 2
Phase 1
Phase 1
Phase 1
Completed
Completed
Completed
Completed
Pegapamodutide
TT-401, OPK-88003, LY-2944876, WG4ID2U7FT
Phase 2 Clinical
Eli Lilly And Company
Diabetes Mellitus, Type 2, Obesity
NCT03406377
NCT02119819
NCT02692781
NCT00239187
NCT02188303
Drug
Drug
Other, Drug
Drug
Drug
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Obesity
Type 2 Diabetes
Healthy Volunteers
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Completed
Completed
Completed
Completed
Terminated
Load More
volagidemab
AMG-477, REMD-477
Phase 2 Clinical
Amgen Inc
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetes Mellitus
NCT03117998
NCT03919617
NCT04545411
NCT02455011
NCT04330625
NCT04253223
NCT02715193
Biological
Drug
Drug
Biological
Biological
Biological
Biological
Type1 Diabetes Mellitus
Type 1 Diabetes Mellitus
Type 1 Diabetes
Type 2 Diabetes Mellitus; Diabetes
Hyperglycemia Drug Induced
Hyperglycemia Drug Induced
Type 1 Diabetes Mellitus; Diabetes
Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Recruiting
Active, not recruiting
Recruiting
Completed
Recruiting
Recruiting
Completed
HM-15211
HM-15211
Phase 2 Clinical
Hanmi Pharmaceutical Co Ltd
Non-alcoholic Fatty Liver Disease, Obesity
NCT04505436
NCT03374241
NCT03744182
NASH - Nonalcoholic Steatohepatitis
Obesity
NAFLD
Recruiting
Unknown status
Completed
HM-15136
HM-15136
Phase 2 Clinical
Hanmi Pharmaceutical Co Ltd
Congenital Hyperinsulinism, Diabetes Mellitus, Type 2, Hyperinsulinism
NCT04732416
NCT04167553
NCT04032782
Congenital Hyperinsulinism
Obese With Comorbidities; Overweight With Comorbidities; Type2 Diabetes
Pharmacology
Not yet recruiting
Active, not recruiting
Completed
Isosteviol
ISV, STX-03
Phase 2 Clinical
Stevia Pharma
Diabetes Mellitus, Type 2
IONIS-GCGRRx
ISISGCGRRx, ISIS-449884, IONIS-GCGRRx
Phase 2 Clinical
Ionis
Diabetes Mellitus, Type 2
NCT02824003
NCT02583919
NCT01885260
NCT00519727
Type 2 Diabetes
Type 2 Diabetes
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Phase 2
Phase 2
Phase 2
Phase 1
Completed
Completed
Completed
Completed
Cotadutide
MEDI-0382
Phase 2 Clinical
Medimmune Llc
Diabetes Mellitus, Type 2, Renal Insufficiency, Non-alcoholic Fatty Liver Disease, Obesity, Renal Insufficiency, Chronic
NCT03596177
NCT03444584
NCT04019561
NCT04515849
NCT03244800
NCT03645421
NCT03235050
NCT03550378
NCT03745937
NCT03555994
NCT02548585
NCT03347968
NCT03235375
NCT02394314
NCT03341013
NCT04208620
NCT03385369
NCT03625778
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Biological, Drug
Drug
Drug
Drug
Drug
Drug
Drug
Diabetes Mellitus, Type II; Obesity
Type 2 Diabetes Mellitus
Non-alcoholic Fatty Liver Disease (NAFLD); Non-alcoholic Steatohepatitis (NASH)
Type 2 Diabetes Mellitus; Chronic Kidney Diseases
Type 2 Diabetes Mellitus
Type 2 Diabetes
Diabetes Mellitus, Type 2
Type II Diabetes Mellitus; Renal Insufficiency
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Healthy Volunteers
Renal Insufficiency
Healthy Volunteers
Type 2 Diabetes Mellitus
Type 2 Diabetes
Safety; Healthy Subjects
Obesity
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Completed
Completed
Active, not recruiting
Recruiting
Completed
Completed
Completed
Completed
Completed
Active, not recruiting
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Oxyntomodulin (Xenetic Biosciences)
Phase 2 Clinical
Pharmsynthez, Xenetic Biosciences
Diabetes Mellitus, Type 2, Obesity
Efinopegdutide
JNJ-5111, HM-12525A, JNJ-64565111
Phase 2 Clinical
Hanmi Pharmaceutical Co Ltd
Diabetes Mellitus, Type 2, Obesity, Kidney Failure, Chronic
NCT03486392
NCT03586830
NCT02862431
NCT03606057
NCT03618160
NCT03235219
NCT03546205
NCT03586843
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Obesity
Obesity and Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Healthy
Healthy
Diabetes Mellitus, Type 2
Kidney Failure, Chronic
Obesity
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Completed
Completed
Terminated
Completed
Terminated
Completed
Completed
Completed
LY-3305677
OXM-3, IBI-362, LY-3305677
Phase 2 Clinical
Eli Lilly And Company
Diabetes Mellitus, Type 2, Obesity, Overweight
NCT04440345
NCT04466904
NCT02972645
NCT04773977
NCT03325387
NCT03928379
Overweight or Obesity
Type 2 Diabetes
Healthy
Overweight/Obesity
Healthy
Diabetes Mellitus, Type 2
Phase 1/Phase 2
Phase 1/Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Recruiting
Recruiting
Completed
Active, not recruiting
Completed
Active, not recruiting
BioChaperone Glucagon
BC Glucagon
Phase 1 Clinical
Adocia
Diabetes Mellitus, Type 1, Hypoglycemia
Load More
NN-9513 (Novo Nordisk)
Phase 1 Clinical
Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemia, Diabetes Mellitus
Diabetes; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2
NN-9277
NN-9277, NNC-9204-1177
Phase 1 Clinical
Novo Nordisk A/S
Obesity, Overweight
NCT04059367
NCT03308721
NCT02941042
Healthy Volunteers; Overweight; Obesity
Metabolism and Nutrition Disorder; Obesity
Metabolism and Nutrition Disorder; Obesity
Completed
Completed
Completed
SAR-441255
SAR-441255
Phase 1 Clinical
Sanofi
Diabetes Mellitus, Type 2, Obesity, Overweight
Overweight; Healthy Subjects
PRT-003
PRT-003
Phase 1 Clinical
Particle Therapeutics
ZP-2929
ZP-2929
Phase 1 Clinical
Zealand Pharma A/S
Diabetes Mellitus, Type 2, Obesity
Glucagon (Translational Research Institute for Metabolism and Diabetes, Florida)
Phase 1 Clinical
Translational Research Institute For Metabolism And Diabetes
Obesity
GLP-1/GIP/glucagon tri-agonist (Lilly)
Phase 1 Clinical
Eli Lilly And Company
Diabetes Mellitus
SP-1373
SP-1373, VOD-107
Preclinical
Velocity Pharmaceutical Development
Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2, Obesity
LY-3185643
LY-3185643
Pending
Eli Lilly And Company
Hypoglycemia
LY-2786890
LY-2786890
Pending
Eli Lilly And Company
Diabetes Mellitus, Type 2
Load More
Stable glucagon (Albireo Pharma)
BIOD-961, BIOD-962
Pending
Albireo
Hypoglycemia
ZP-1-98 (Zealand Pharma)
ZP-1-98, ZP-2435, ZP-DI-70
Pending
Zealand Pharma A/S
Diabetes Mellitus, Type 2, Obesity
ZP-3022 (Zealand Pharma)
ZP-3022
Pending
Zealand Pharma A/S
Diabetes Mellitus, Type 2, Obesity
TKS-1225
TKS-1225
Pending
Pfizer Pharmaceuticals Ltd (China)
Obesity
Glucagon analogue
G-530-L, NN-9030, NNC9204-0530
Pending
Novo Nordisk A/S
Obesity
NCT02835235
NCT02870231
NCT02235961
Metabolism and Nutrition Disorder; Obesity
Metabolism and Nutrition Disorder; Obesity
Metabolism and Nutrition Disorder; Obesity
Completed
Completed
Completed
Oxyntomodulin long-acting (OPKO Health)
MOD-6031
Pending
Opko Health
Obesity
LY-3143753
LY-3143753
Pending
Eli Lilly And Company
Hypoglycemia
Adomeglivant
74Z5ZL2KVG, LY-2409021
Discontinued
Eli Lilly And Company
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Kidney Failure, Chronic
NCT01241448
NCT00871572
NCT02091362
NCT02111096
NCT01460368
NCT01606371
NCT01588366
NCT02385084
NCT01606423
NCT01606397
NCT01354496
NCT02217618
NCT01836198
NCT01929109
NCT01640834
NCT02669524
NCT02944110
NCT02792400
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Drug
Procedure, Drug
Drug
Procedure, Drug
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Healthy
Healthy Volunteers
Diabetes Mellitus, Type 2
Healthy Volunteers
Healthy Participants
Healthy Volunteers
Kidney Failure, Chronic; Renal Insufficiency, Chronic
Diabetes Mellitus, Type 1
Type 2 Diabetes
Diabetes After Total Pancreatectomy
Type 2 Diabetes
Phase 2
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
Phase 1
N/A
N/A
N/A
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Terminated
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Completed
Enrolling by invitation
Completed
Crotedumab
REGN-1193
Discontinued
Sanofi, Regeneron Pharmaceuticals Inc
Diabetes Mellitus, Type 2
Healthy Volunteers
Diabetes Mellitus, Type 2
Glucagon biosimilar (Hospira)
Discontinued
Hospira
Hypoglycemia
Load More
Glucagon (intranasal, Organon)
Discontinued
Organon
Diabetes Mellitus, Type 1, Gastrointestinal Diseases
SAR-425899
SAR-425899
Discontinued
Sanofi
Non-alcoholic Fatty Liver Disease, Diabetes Mellitus, Type 2
NCT03437720
NCT02973321
NCT03376802
NCT03414736
NCT02411825
NCT03350191
Non-alcoholic Steatohepatitis; Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Phase 1
Withdrawn
Completed
Completed
Completed
Completed
Completed
VLD-glucagon
DIO-901
Discontinued
Diobex
Diabetes Mellitus, Type 1, Hypoglycemia
BAY-27-9955
BAY-27-9955
Discontinued
Bayer Ag
Diabetes Mellitus, Type 2
MK-8521
MK-8521
Discontinued
Merck Sharp & Dohme Corp
Diabetes Mellitus, Type 2, Diabetes Mellitus
NCT02492763
NCT01982630
NCT02055547
Type II Diabetes Mellitus
Diabetes Mellitus
Type 2 Diabetes Mellitus
Terminated
Completed
Completed
PF-06291874
PF-6291874, PF-06291874
Discontinued
Pfizer Inc
Diabetes Mellitus, Type 2
NCT02175121
NCT02554877
NCT01794364
NCT01856595
NCT01499017
Drug
Drug
Other, Drug
Drug
Drug
Diabetes Mellitus, Type II
Type 2 Diabetes Mellitus
Healthy
Diabetes Mellitus, Type 2
Healthy
Phase 2
Phase 2
Phase 1
Phase 1
Phase 1
Completed
Completed
Completed
Completed
Terminated
MK-3577
MK-3577
Discontinued
Merck Sharp & Dohme Corp
Diabetes Mellitus, Type 2
MK-0893
MK-0893, L-001241689
Discontinued
Merck & Co Inc
Diabetes Mellitus, Type 2
NCT02004886
NCT00631488
NCT00479466
NCT00902161
NCT02012166
Drug
Drug
Drug
Drug
Biological, Drug
Type 2 Diabetes Mellitus
Diabetes Mellitus, Type 2
Diabetes Mellitus, Type 2
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus
Phase 2
Phase 2
Phase 2
Phase 1
Phase 1
Completed
Completed
Terminated
Completed
Completed
ISIS-325568
ISIS-325568
Discontinued
Ionis
Diabetes Mellitus, Type 2
NN-2501
NN-2501
Discontinued
Novo Nordisk A/S
Diabetes Mellitus, Type 2
Load More